Verrica Pharmaceuticals (VRCA)
(Delayed Data from NSDQ)
$8.31 USD
-0.27 (-3.15%)
Updated Jun 4, 2024 04:00 PM ET
After-Market: $8.27 -0.04 (-0.48%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Brokerage Reports
0 items in cart
Verrica Pharmaceuticals Inc. [VRCA]
Reports for Purchase
Showing records 21 - 32 ( 32 total )
Company: Verrica Pharmaceuticals Inc.
Industry: Medical - Drugs
Company: Verrica Pharmaceuticals Inc.
Industry: Medical - Drugs
Company: Verrica Pharmaceuticals Inc.
Industry: Medical - Drugs
FDA Indicates YCANTH Device Issue(s) Will Preclude July Approval; For Now, We Push Launch to Late-2021; Lower to $18
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Verrica Pharmaceuticals Inc.
Industry: Medical - Drugs
We Leave Room for COVID Delays With First Revenue in 2021; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Verrica Pharmaceuticals Inc.
Industry: Medical - Drugs
4Q19; July 13 YCANTH PDUFA; Our Projections Already Leave Room for Potential COVID Related Approval Delay; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Verrica Pharmaceuticals Inc.
Industry: Medical - Drugs
VP-102 NDA Accepted With July 2020 PDUFA; Reiterate Buy;
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Verrica Pharmaceuticals Inc.
Industry: Medical - Drugs
VP-102 NDA for Molluscum Filed; We See Relatively Low- Risk Approval and $400M Peak Sales
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Verrica Pharmaceuticals Inc.
Industry: Medical - Drugs
2Q Results; Valuation Disconnect With VP-102 NDA Filing Imminent; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Verrica Pharmaceuticals Inc.
Industry: Medical - Drugs
VP-102 Peak Potential Climbs With Positive Warts Data; Raise to $23
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Verrica Pharmaceuticals Inc.
Industry: Medical - Drugs
Relative Weakness Unexplained; Molluscum Undervalued; We See Low-Risk 2020 Approval; Near-Term Warts Data Would Be Icing
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Verrica Pharmaceuticals Inc.
Industry: Medical - Drugs
4Q18 Results; General Warts Data 2Q19, Molluscum Lead Asset NDA Filing 2H19
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O
Company: Verrica Pharmaceuticals Inc.
Industry: Medical - Drugs
Beetlejuice, Beetlejuice, Beetlejuice for Molluscum; Initiate With Buy and $20 Target
Provider: H.C. Wainwright & Co., Inc.
Analyst: LIVNAT O